Table of Contents Author Guidelines Submit a Manuscript
Journal of Interventional Cardiology
Volume 2019, Article ID 6704031, 7 pages
https://doi.org/10.1155/2019/6704031
Research Article

Left Atrial Appendage Occlusion in High Bleeding Risk Patients

1Department of Cardiology, Ospedale San Francesco, Nuoro, Italy
2Istituto di Clinica Medica, Azienda Ospedaliero-Universitaria di Sassari, Sassari, Italy
3Neurology Department and Stroke Unit, Ospedale San Francesco, Nuoro, Italy
4Arrhythmology and Cardiac Pacing Unit, Cardiothoracic and Vascular Department, IRCCS Ospedale San Raffaele, Milan, Italy

Correspondence should be addressed to Pierluigi Merella; ti.liamtoh@9igiulreip

Received 20 May 2018; Revised 27 January 2019; Accepted 6 February 2019; Published 18 February 2019

Academic Editor: Andrea Rubboli

Copyright © 2019 Pierluigi Merella et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Miyasaka, M. E. Barnes, B. J. Gersh et al., “Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence,” Circulation, vol. 114, no. 11, pp. 119–125, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Heeringa, D. A. M. van der Kuip, A. Hofman et al., “Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study,” European Heart Journal, vol. 27, no. 8, pp. 949–953, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Colilla, A. Crow, W. Petkun, D. E. Singer, T. Simon, and X. Liu, “Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population,” The American Journal of Cardiology, vol. 112, no. 8, pp. 1142–1147, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Kirchhof, S. Benussi, D. Kotecha et al., “2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS,” European heart journal, vol. 37, no. 6, pp. 2893–2962, 2016. View at Publisher · View at Google Scholar
  5. A. P. Delitala, “Subclinical Hyperthyroidism and the Cardiovascular Disease,” Hormone and Metabolic Research, vol. 49, no. 10, pp. 723–731, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. T.-F. Chao, G. Y. H. Lip, C.-J. Liu et al., “Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation,” Journal of the American College of Cardiology, vol. 71, no. 2, pp. 122–132, 2018. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Shang, L. Li, S. Huang et al., “Chronic kidney disease and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies,” PLoS One, vol. 11, no. 5, p. e0155581, 2016. View at Publisher · View at Google Scholar
  8. J. D. Miller, K. N. Aronis, J. Chrispin et al., “Obesity, Exercise, Obstructive Sleep Apnea, and Modifiable Atherosclerotic Cardiovascular Disease Risk Factors in Atrial Fibrillation,” Journal of the American College of Cardiology, vol. 66, no. 25, pp. 2899–2906, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Y. Lip, R. Nieuwlaat, R. Pisters, D. A. Lane, and H. J. Crijns, “Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation,” Chest, vol. 137, no. 2, pp. 263–272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. C. T. January, L. S. Wann, J. S. Alpert et al., “2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the american college of cardiology/american heart association task force on practice guidelines and the heart rhythm society,” Circulation, vol. 130, no. 23, pp. 2071–2104, 2014. View at Publisher · View at Google Scholar
  11. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., “Dabigatran versus warfarin with atrial fibrillation,” The New England Journal of Medicine, vol. 361, pp. 1139–1151, 2009. View at Publisher · View at Google Scholar
  12. M. R. Patel, K. W. Mahaffey, J. Garg et al., “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation,” The New England Journal of Medicine, vol. 365, no. 24, pp. 883–891, 2011. View at Publisher · View at Google Scholar
  13. C. B. Granger, J. H. Alexander, J. J. McMurray et al., “Apixaban versus warfarin in patients with atrial fibrillation,” The New England journal of medicine, vol. 365, pp. 981–992, 2011. View at Publisher · View at Google Scholar
  14. R. P. Giugliano, C. T. Ruff, and E. Braunwald, “Edoxaban versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 369, pp. 2093–2104, 2013. View at Publisher · View at Google Scholar
  15. C. T. Ruff, R. P. Giugliano, E. Braunwald et al., “Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials,” The Lancet, vol. 383, no. 9921, pp. 955–962, 2014. View at Publisher · View at Google Scholar
  16. G. Y. H. Lip, L. Frison, J. L. Halperin, and D. A. Lane, “Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score,” Journal of the American College of Cardiology, vol. 57, no. 2, pp. 173–180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Merella, G. Lorenzoni, N. Marziliano et al., “Nonvalvular atrial fibrillation in high-hemorrhagic-risk patients: state of the art of percutaneous left atrial appendage occlusion,” Journal of Cardiovascular Medicine, vol. 20, no. 1, pp. 1–9, 2018. View at Publisher · View at Google Scholar
  18. N. Weis, S. Cowan, S. Hallager et al., “Vertical transmission of hepatitis B virus during pregnancy and delivery in Denmark,” Scandinavian Journal of Gastroenterology, vol. 52, no. 2, pp. 178–184, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. C. V. DeSimone, J. Graff-Radford, M. A. El-Harasis, A. A. Rabinstein, S. J. Asirvatham, and D. R. Holmes, “Cerebral amyloid angiopathy: diagnosis, clinical implications, and management strategies in atrial fibrillation,” Journal of the American College of Cardiology, vol. 70, no. 9, pp. 1173–1182, 2017. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Ronco, P. Mazzone, L. Hosseinian, and S. Genovesi, “Recent advances in stroke prevention in patients with atrial fibrillation and end-stage renal disease,” Cardiorenal Medicine, vol. 7, no. 3, pp. 207–217, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Merella, G. Casu, P. Mazzone et al., “Atrial fibrillation in severe and end stage renal disease: from oral anticoagulation therapy to percutaneous left atrial appendage occlusion,” Giornale Italiano Di Nefrologia: Organo Ufficiale Della Societa Italiana Di Nefrologia, 2019. View at Publisher · View at Google Scholar
  22. S. Genovesi, G. Slaviero, L. Porcu et al., “Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: Peri-procedural outcomes from an Italian dialysis population,” International Journal of Cardiology, vol. 262, pp. 38–42, 2018. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Casu, M. M. Gulizia, G. Molon et al., “ANMCO/AIAC/SICI-GISE/SIC/SICCH consensus document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: Indications, patient selection, staff skills, organisation, and training,” European Heart Journal Supplements: Journal of the European Society of Cardiology, vol. 19, pp. D333–D353, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Casu, M. M. Gulizia, G. Molon et al., “ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus document: Percutaneous left atrial appendage occlusion in patients with nonvalvular atrial fibrillation: Indications, patient selection, competences, organization, and operator training,” Giornale Italiano di Cardiologia, vol. 17, no. 7-8, pp. 594–613, 2016. View at Google Scholar · View at Scopus
  25. B. Meier, Y. Blaauw, A. A. Khattab et al., “EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion,” Europace, vol. 16, no. 10, pp. 1397–1416, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. J. L. Blackshear and J. A. Odell, “Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation,” The Annals of Thoracic Surgery, vol. 61, no. 2, pp. 755–759, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Y. Reddy, S. K. Doshi, H. Sievert et al., “Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation 2.3-year follow-up of the PROTECT AF (Watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial,” Circulation, vol. 127, no. 6, pp. 720–729, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. L. V. Boersma, H. Ince, S. Kische et al., “Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial,” Heart Rhythm, vol. 14, no. 9, pp. 1302–1308, 2017. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Tzikas, S. Shakir, S. Gafoor et al., “Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug,” EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, vol. 11, pp. 1170–1179, 2016. View at Google Scholar
  30. V. Y. Reddy, D. Holmes, S. K. Doshi, P. Neuzil, and S. Kar, “Safety of percutaneous left atrial appendage closure: Results from the watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the continued access registry,” Circulation, vol. 123, no. 4, pp. 417–424, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. L. V. A. Boersma, B. Schmidt, T. R. Betts et al., “Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry,” European Heart Journal, vol. 37, no. 31, pp. 2465–2474, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Lorenzoni, P. Merella, P. Pischedda, and G. Casu, “Percutaneous Management of Left Atrial Appendage Perforation: Keep Calm and Think Fast,” Journal of Invasive Cardiology, vol. 30, pp. E126–E127, 2018. View at Google Scholar
  33. M. Lempereur, A. Aminian, X. Freixa et al., “Device-associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet,” Catheterization and Cardiovascular Interventions, vol. 90, no. 1, pp. E111–E121, 2017. View at Publisher · View at Google Scholar · View at Scopus
  34. M. W. Bergmann, T. R. Betts, H. Sievert et al., “Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: Three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry,” EuroIntervention, vol. 13, no. 7, pp. 877–884, 2017. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Ahmad, O. Demir, C. Rajkumar et al., “Optimal antiplatelet strategy after transcatheter aortic valve implantation: a meta-analysis,” Open Heart, vol. 5, no. 1, p. e000748, 2018. View at Publisher · View at Google Scholar
  36. K. Korsholm, K. M. Nielsen, J. M. Jensen, H. K. Jensen, G. Andersen, and J. E. Nielsen-Kudsk, “Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy,” EuroIntervention:Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, vol. 12, no. 17, pp. 2075–2082, 2017. View at Publisher · View at Google Scholar · View at Scopus
  37. G. W. Reed and C. P. Cannon, “Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting,” Clinical Cardiology, vol. 36, pp. 585–594, 2013. View at Publisher · View at Google Scholar